We have shown that the N′-propylhydrazide analog of hydroxamic inhibitor belinostat (hydrazostat, previously described as belinostat-PH) is a potent HDAC class I inhibitor with negligible off-target activities across the other HDACs in human hepatoma cells [33]. The gene discussed is HDAC9; the disease is hepatocellular carcinoma.